First-in-class oral drug improves embryo implantation and pregnancy outcomes in IVF

FHS
July 8, 2024
2:22 pm

New research has demonstrated the effectiveness of a first-in-class oral, non-hormonal drug in increasing embryo implantation, pregnancy and live birth rates among infertile women who are undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Older Adults Most Concerned About Healthcare Costs Ahead of Election

Ahead of the 2024 election, five of the top six health concerns of adults 50 years and older were related to costs of healthcare and

August 15, 2024

Novo touts early data for next-gen oral weight loss drug as it outlines next steps

Novo Nordisk’s oral amycretin showed a 13.1% weight loss in patients after just 12 weeks in a small Phase I trial, the company revealed at

March 8, 2024

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Half Year Results 21.10.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement.

October 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.